Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Department of Nuclear Medicine, Policlinico S. Orsola, University of Bologna, Bologna, Italy.
Eur Urol Oncol. 2021 Jun;4(3):370-395. doi: 10.1016/j.euo.2020.11.002. Epub 2020 Dec 4.
Management of newly diagnosed prostate cancer (PCa) is guided in part by accurate clinical staging. The role of imaging, including magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT), in initial staging remains controversial.
To systematically review the studies of MRI and/or PET/CT in the staging of newly diagnosed PCa with respect to tumor (T), nodal (N), and metastatic (M) staging (TNM staging).
We performed a systematic review of the literature using MEDLINE and Web of Science databases between 2012 and 2020 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement guidelines.
A total of 139 studies (83 on T, 47 on N, and 24 on M status) were included. Ninety-nine (71%) were retrospective, 39 (28%) were prospective, and one was a randomized controlled trial (RCT). Most studies on T staging examined MRI, while PET/CT was used primarily for N and M staging. Sensitivity for the detection of extraprostatic extension, seminal vesicle invasion, or lymph node invasion ranged widely. When imaging was incorporated into existing risk tools, gain in accuracy was observed in some studies, although these findings have not been replicated. For M staging, most favorable results were reported for prostate-specific membrane antigen (PSMA) PET/CT, which demonstrated significantly better performance than conventional imaging.
A variety of studies on modern imaging techniques for TNM staging in newly diagnosed PCa exist. For T and N staging, reported sensitivity of imaging modalities such as MRI or PET/CT varied widely due to data heterogeneity, small sample size, and low event rates resulting in large confidence intervals and a high level of uncertainty. Therefore, uniformity in data presentation and standardization on this topic are needed. The most promising technique for M staging, which was evaluated recently in an RCT, is PSMA-PET/CT.
We performed a systematic review of currently available imaging modalities to stage newly diagnosed prostate cancer. With respect to local tumor and lymph node assessment, performance of imaging ranged widely. However, prostate-specific membrane antigen positron emission tomography/computed tomography showed favorable results for the detection of distant metastases.
新诊断前列腺癌(PCa)的管理部分取决于准确的临床分期。影像学(包括磁共振成像[MRI]和正电子发射断层扫描/计算机断层扫描[PET/CT])在初始分期中的作用仍存在争议。
系统评价 MRI 和/或 PET/CT 在新诊断 PCa 的分期中的作用,包括肿瘤(T)、淋巴结(N)和远处转移(M)分期(TNM 分期)。
我们按照系统评价和荟萃分析的首选报告项目(PRISMA)声明指南,使用 MEDLINE 和 Web of Science 数据库在 2012 年至 2020 年期间进行了文献系统评价。
共纳入 139 项研究(83 项关于 T 分期,47 项关于 N 分期,24 项关于 M 状态)。99 项(71%)为回顾性研究,39 项(28%)为前瞻性研究,1 项为随机对照试验(RCT)。大多数关于 T 分期的研究检查了 MRI,而 PET/CT 主要用于 N 和 M 分期。检测前列腺外延伸、精囊侵犯或淋巴结侵犯的敏感性差异很大。当影像学纳入现有的风险工具时,一些研究观察到准确性的提高,尽管这些发现尚未得到复制。对于 M 分期,大多数有利的结果是报道前列腺特异性膜抗原(PSMA)PET/CT,其表现明显优于传统影像学。
存在多种关于新诊断 PCa 的 TNM 分期的现代影像学技术的研究。对于 T 和 N 分期,由于数据异质性、样本量小以及导致置信区间大且不确定性高的低事件率,MRI 或 PET/CT 等影像学手段的报道敏感性差异很大。因此,需要在这个主题上统一数据呈现和标准化。在最近的 RCT 中评估的最有前途的 M 分期技术是 PSMA-PET/CT。
我们对目前可用的影像学检查方法进行了系统评价,以分期新诊断的前列腺癌。对于局部肿瘤和淋巴结评估,影像学表现差异很大。然而,前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在检测远处转移方面显示出良好的效果。